Construction And Use Of Recombinant Parainfluenza Viruses Expressing A Chimeric Glycoprotein


Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome modified to encode a chimeric glycoprotein incorporating one or more heterologous antigenic domains, fragments, or epitopes of a second, antigenically distinct HPIV. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting an immune responses against one or more PIVs, and, optionally against respiratory syncytial virus (RSV). Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a HPIV vector genome or antigenome combined or integrated with one or more heterologous genome segment(s) encoding one or more antigenic determinant(s) of a heterologous PIV to encode a chimeric glycoprotein. In preferred aspects of the invention, the chimeric virus is attenuated for use as a vaccine agent by additional mutations or nucleotide modifications introduced into the chimeric genome or antigenome.

Download PDF
Document Preview
Document History
  • Publication: Jul 31, 2007
  • Application: Dec 10, 1999
    US US 45906299 A
  • Priority: Dec 10, 1999
    US US 45906299 A
  • Priority: May 22, 1998
    US US 8379398 A
  • Priority: Sep 19, 1997
    US US 5938597 P
  • Priority: May 23, 1997
    US US 4757597 P

Download Citation

Sign in to the Lens